Director Declaration

18 August 2016 13:00

 

New external board appointment 

Listing Rule LR 9.6.14 R (2)

Graham Chipchase, a Non-Executive Director of AstraZeneca PLC, has been appointed as Chief Executive Officer and a Director of Brambles Limited, a company listed on the Australian Securities Exchange, effective from 2017.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory and Autoimmunity, Cardiovascular and Metabolic Diseases, and Oncology. The Company is also active in inflammation, infection and neuroscience through numerous collaborations. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com    

CONTACTS

Media Enquiries           
Neil Burrows    UK/Global    +44 203 749 5637   
Vanessa Rhodes    UK/Global    +44 203 749 5736   
Karen Birmingham    UK/Global    +44 203 749 5634   
Rob Skelding    UK/Global    +44 203 749 5821   
Jacob Lund    Sweden    +46 8 553 260 20   
Michele Meixell    US    +1 302 885 2677   
Investor Relations
UK
Thomas Kudsk Larsen   +44 203 749 5712 
Craig Marks  Finance, Fixed Income, M&A +44 7881 615 764 
Nick Stone  Respiratory & Autoimmunity +44 203 749 5716 
Henry Wheeler  Oncology  +44 203 749 5797 
Christer Gruvris Infection & Neuroscience +44 203 749 5711
US
Lindsey Trickett  Cardiovascular & Metabolic   Diseases +1 240 543 7970
Mitchell Chan   Oncology +1 240 477 3771
Toll-free +1 866 381 7277

Adrian Kemp

Company Secretary

AstraZeneca PLC

-ENDS-

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com

Subscribe

Documents & Links